Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? (Q34726350)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

object named as

Bo Ahrén

1 reference

Europe PubMed Central

4 August 2017

author name string

James Edward Foley

2

1 reference

Europe PubMed Central

4 August 2017

Sylvie Dejager

3

1 reference

Europe PubMed Central

4 August 2017

Mouna Akacha

4

1 reference

Europe PubMed Central

4 August 2017

Qing Shao

5

1 reference

Europe PubMed Central

4 August 2017

Guenter Heimann

6

1 reference

Europe PubMed Central

4 August 2017

Markus Dworak

7

1 reference

Europe PubMed Central

4 August 2017

Anja Schweizer

8

1 reference

Europe PubMed Central

4 August 2017

publication date

18 September 2014

1 reference

Europe PubMed Central

4 August 2017

Diabetes Therapy

1 reference

Europe PubMed Central

4 August 2017

5

1 reference

Europe PubMed Central

4 August 2017

2

1 reference

Europe PubMed Central

4 August 2017

459-469

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution 4.0 International

18 September 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s13300-014-0082-y

0 references

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Oral Antidiabetic Agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25230877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25230877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13300-014-0082-Y

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34726350&oldid=1981153528"